Daewon Pharm (003220) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daewon Pharm (003220) has a cash flow conversion efficiency ratio of -0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-17.26 Billion ≈ $-11.69 Million USD) by net assets (₩263.87 Billion ≈ $178.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Daewon Pharm - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Daewon Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Daewon Pharm total liabilities for a breakdown of total debt and financial obligations.
Daewon Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daewon Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Surya Fajar Capital Tbk PT
JK:SFAN
|
0.016x |
|
Baran Group Ltd
TA:BRAN
|
-0.136x |
|
Groupe Sfpi
PA:SFPI
|
0.026x |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
0.035x |
|
Habco Trans Maritima
JK:HATM
|
0.017x |
|
China ZhengTong Auto Services Holdings Limited
F:ZA0
|
-0.135x |
|
Paragon Globe Bhd
KLSE:3611
|
-0.008x |
|
BioInvent International AB
ST:BINV
|
0.082x |
Annual Cash Flow Conversion Efficiency for Daewon Pharm (2011–2024)
The table below shows the annual cash flow conversion efficiency of Daewon Pharm from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Daewon Pharm.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩284.58 Billion ≈ $192.85 Million |
₩30.04 Billion ≈ $20.35 Million |
0.106x | -46.09% |
| 2023-12-31 | ₩264.26 Billion ≈ $179.09 Million |
₩51.73 Billion ≈ $35.06 Million |
0.196x | +46.13% |
| 2022-12-31 | ₩248.77 Billion ≈ $168.58 Million |
₩33.33 Billion ≈ $22.58 Million |
0.134x | +30.54% |
| 2021-12-31 | ₩218.40 Billion ≈ $148.01 Million |
₩22.41 Billion ≈ $15.19 Million |
0.103x | -12.49% |
| 2020-12-31 | ₩212.77 Billion ≈ $144.19 Million |
₩24.95 Billion ≈ $16.91 Million |
0.117x | -22.67% |
| 2019-12-31 | ₩204.22 Billion ≈ $138.39 Million |
₩30.97 Billion ≈ $20.99 Million |
0.152x | -30.60% |
| 2018-12-31 | ₩183.20 Billion ≈ $124.15 Million |
₩40.03 Billion ≈ $27.13 Million |
0.219x | +761.41% |
| 2017-12-31 | ₩168.13 Billion ≈ $113.94 Million |
₩4.27 Billion ≈ $2.89 Million |
0.025x | -80.23% |
| 2016-12-31 | ₩162.01 Billion ≈ $109.79 Million |
₩20.79 Billion ≈ $14.09 Million |
0.128x | -26.10% |
| 2015-12-31 | ₩148.66 Billion ≈ $100.75 Million |
₩25.82 Billion ≈ $17.50 Million |
0.174x | +33.89% |
| 2014-12-31 | ₩134.51 Billion ≈ $91.16 Million |
₩17.45 Billion ≈ $11.82 Million |
0.130x | +29.76% |
| 2013-12-31 | ₩123.25 Billion ≈ $83.53 Million |
₩12.32 Billion ≈ $8.35 Million |
0.100x | -18.36% |
| 2012-12-31 | ₩112.92 Billion ≈ $76.53 Million |
₩13.83 Billion ≈ $9.37 Million |
0.122x | -29.04% |
| 2011-12-31 | ₩103.92 Billion ≈ $70.42 Million |
₩17.93 Billion ≈ $12.15 Million |
0.173x | -- |
About Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more